GemPharmatech

Executive Summary

GemPharmatech is a leading contract research organization (CRO) specializing in genetically engineered mouse models (GEMMs) and preclinical research services. Founded in 2017 and headquartered in Nanjing, China, the company serves the global preclinical R&D community with a vast repository of over 25,000 mouse strains. By leveraging cutting-edge gene-editing technologies, GemPharmatech provides customized model generation, breeding, and preclinical testing solutions, enabling pharmaceutical and biotechnology companies to accelerate drug discovery and development. With a focus on quality and innovation, the company has established itself as a key player in the preclinical CRO space, particularly in oncology, immunology, and neuroscience. Despite being private, GemPharmatech has demonstrated strong growth potential, supported by increasing demand for specialized animal models and the expansion of its service offerings to global clients.

Upcoming Catalysts (preview)

• Q3 2026Expansion of U.S. Operations or Major Partnership70% success
• TBDLaunch of Next-Generation Gene-Editing Platform60% success
• Q1 2027Strategic Collaboration with Top-20 Pharma Company50% success